<DOC>
	<DOCNO>NCT01562613</DOCNO>
	<brief_summary>The primary objective study evaluate proportion hypertensive patient achieve regulation blood pressure ( BP ) level accord European Society Cardiology / European School Haematology ( ESC/ESH ) Guidelines , treatment eprosartan 6 month standard medical practice condition . The absolute change Systolic blood pressure baseline also calculate . This study also aim evaluation Framingham stroke risk profile score patient treat eprosartan standard clinical practice condition observation period . Besides primary secondary objective study , assessment percentage patient experience Adverse Events ( AEs ) , Serious Adverse Events ( SAEs ) , Adverse Drug Reactions ( ADRs ) , Serious Adverse Drug Reactions ( SADRs ) ( overall per observed event ) percentage patient discontinue treatment prematurely advent 6-month observation period due toxicity study medication constitute another important objective relate safety treatment .</brief_summary>
	<brief_title>A Blood Pressure Regulation Stroke Risk Evaluation Study Hypertensive Patients Treated With Eprosartan</brief_title>
	<detailed_description>This open , non-interventional , non-comparative study . Therefore , control group , randomization , blind involve . The target subject population hypertensive patient treat eprosartan standard clinical condition locally approve Summary Product Characteristics ( SmPCs ) . Treatment selection independent study conduct accord local requirement Health Authorities definition non-interventional study conduct Greece . Therefore , inclusion/exclusion criterion study follow clinical decision participate physician , prescribe study medication ( ) standard clinical practice . The study plan enroll 600 patient 100 participate center ( hospital private physician ) . This number include additional 25 % cushion compare required sample size ensure sufficient data collect subsequent statistical analysis . The study design non-interventional subsequently follow per center standard practice treatment , medical care visit . As result rigid visit schedule could impose . However , take account overall local standard practice , overview visit schedule indicate per subject : - A baseline visit begin 6-month observation period investigator check eligibility subject record baseline data provide subject eligible give sign date informed consent . - A final visit end 6-month treatment period ( also observation period ) , - At least one interim visit ( accord standard clinical practice , within baseline final visit )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Eprosartan</mesh_term>
	<criteria>1 . Adult patient ( age great equal 18 year ) 2 . Hypertensive patient , sit Systolic Blood Pressure 140 mmHg 130 mmHg diabetic high/very high risk patient , accord ESC/ESH Guidelines 3 . Patients prescribed eprosartan term condition local label administer accord standard medical practice 4 . Patients least one follow condition : Newly diagnose hypertension , Inability tolerate antihypertensive medication , Lack response current antihypertensive medication ( ) 1 . Any contraindication eprosartan excipients ( accord local label )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Hypertension</keyword>
</DOC>